Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
BioSante Pharmaceuticals comments on data from Women's Health Initiative study
May 18th, 2006
BioSante Pharmaceuticals, Inc., (BPA) offered comment on new data from the Women's Health Initiative (WHI) study, published in the Journal of the American Medical Association (JAMA), demonstrating that estrogen-alone therapy did not increase breast cancer incidence in postmenopausal women after an average of 7.1 years. The authors also suggest a possible protective effect of estrogen-alone therapy against breast cancer incidence among study participants in the following risk categories: women with a low 5-year estimated risk of developing breast cancer as measured by the Gail Risk Score, women with no first-degree relatives with breast cancer, and women with no...
Source: Biotech Business Week (2006-05-18)
|
